ContraFect Corporation

07/19/2021 | Press release | Distributed by Public on 07/19/2021 09:02

Synergistic anti-biofilm activity of exebacase and rifampin, vancomycin or daptomycin against Staphylococcus epidermidis strains responsible for bone and joint infections